Detalhe da pesquisa
1.
A Tumor-Agnostic NTRK (TRK) Inhibitor.
Cell
; 177(1): 8, 2019 03 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-30901551
2.
Oncogenic Role of THOR, a Conserved Cancer/Testis Long Non-coding RNA.
Cell
; 186(19): 4254-4255, 2023 Sep 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37714137
3.
Risk SNP-Mediated Promoter-Enhancer Switching Drives Prostate Cancer through lncRNA PCAT19.
Cell
; 174(3): 564-575.e18, 2018 07 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-30033362
4.
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.
Cell
; 173(7): 1770-1782.e14, 2018 06 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-29906450
5.
Oncogenic Role of THOR, a Conserved Cancer/Testis Long Non-coding RNA.
Cell
; 171(7): 1559-1572.e20, 2017 Dec 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-29245011
6.
Integrative clinical genomics of advanced prostate cancer.
Cell
; 161(5): 1215-1228, 2015 May 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-26000489
7.
Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer.
Nature
; 608(7921): 199-208, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35859180
8.
Integrative Clinical Genomics of Advanced Prostate Cancer.
Cell
; 162(2): 454, 2015 Jul 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-28843286
9.
Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer.
Nature
; 571(7765): 413-418, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31243372
10.
Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC).
Br J Cancer
; 130(1): 53-62, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37980367
11.
Body composition and mortality in men receiving prostate radiotherapy: A pooled analysis of NRG/RTOG 9406 and NRG/RTOG 0126.
Cancer
; 129(5): 685-696, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36579470
12.
Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function.
Mol Cell
; 58(6): 925-34, 2015 Jun 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-26091341
13.
Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance.
Proc Natl Acad Sci U S A
; 117(22): 12315-12323, 2020 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32424106
14.
Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis.
Lancet Oncol
; 23(2): 304-316, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35051385
15.
Genomic biomarkers to guide precision radiotherapy in prostate cancer.
Prostate
; 82 Suppl 1: S73-S85, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35657158
16.
Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis.
Lancet Oncol
; 22(3): 402-410, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33662287
17.
Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancer.
Cancer
; 127(12): 1965-1973, 2021 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33690902
18.
A bicentric retrospective analysis of clinical utility of 18F-fluciclovine PET in biochemically recurrent prostate cancer following primary radiation therapy: is it helpful in patients with a PSA rise less than the Phoenix criteria?
Eur J Nucl Med Mol Imaging
; 48(13): 4463-4471, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34091713
19.
False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial.
Eur J Nucl Med Mol Imaging
; 48(2): 501-508, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32808077
20.
Genomic and clinical characterization of stromal infiltration markers in prostate cancer.
Cancer
; 126(7): 1407-1412, 2020 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31905251